ANI Pharmaceuticals Bids $560 Million for Rare-Disease Specialist Egetis
- ANI Pharmaceuticals offered to buy Egetis Therapeutics for $560 million, at 11.25 Swedish krona a share, a 27% premium to the two-month average price.
- Egetis sells Emcitate, the only treatment approved in the US and Europe for peripheral thyrotoxicosis in Allan-Herndon-Dudley syndrome; ANI expects peak annual sales of up to $300 million.
💡 Points Based on public reports
ANI is moving from generics toward branded rare disease, buying an approved product rather than a pipeline. The $300 million peak figure is ANI's own and rests on a very small patient pool, so the price implies near-full penetration; the 27% premium is thin for a Swedish-listed target, leaving room for a competing bid or holdouts.
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down ↗